Literature DB >> 1668812

Behavioural effects of selective tachykinin agonists in midbrain dopamine regions.

A J Stoessl1, E Szczutkowski, B Glenn, I Watson.   

Abstract

The effects of selective NK-1, NK-2 and NK-3 tachykinin agonists in midbrain dopamine cell containing regions were investigated in the rat. The NK-3 agonist senktide induced locomotion, rearing and sniffing following infusion into the substantia nigra pars compacta, and to a lesser extent in the ventral tegmental area. These behavioural responses were not seen following infusion of the selective NK-1 agonist [Sar9,Met (O2)11]SP or the NK-2 agonist [N1e10]NKA4-10. In contrast, grooming was induced only by the NK-1 agonist administered into the substantia nigra. Yawning, chewing mouth movements and wet dog shakes were all seen following infusion of senktide into the ventral tegmental area. These findings suggest that (i) dopamine-mediated behavioural responses seen following tachykinin administration into the midbrain are dependent upon stimulation of NK-3 tachykinin receptors, (ii) tachykinin-induced grooming is mediated by stimulation of NK-1 receptors and (iii) some of the previously described 5-HT mediated behaviours seen following administration of NK-3 tachykinin agonists are probably generated by stimulation of 5-HT cell bodies in the ventral tegmental area.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1668812     DOI: 10.1016/0006-8993(91)91657-m

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Characterization of nuclear neurokinin 3 receptor expression in rat brain.

Authors:  C D Sladek; W Stevens; S R Levinson; Z Song; D D Jensen; F W Flynn
Journal:  Neuroscience       Date:  2011-09-08       Impact factor: 3.590

2.  Distinct presynaptic control of dopamine release in striosomal- and matrix-enriched areas of the rat striatum by selective agonists of NK1, NK2, and NK3 tachykinin receptors.

Authors:  L Tremblay; M L Kemel; M Desban; C Gauchy; J Glowinski
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

3.  Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat.

Authors:  E Cellier; L Barbot; S Iyengar; R Couture
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

4.  Distinct Encoding of Reward and Aversion by Peptidergic BNST Inputs to the VTA.

Authors:  Marta E Soden; Joshua X Yee; Beatriz Cuevas; Ariana Rastani; Jordan Elum; Larry S Zweifel
Journal:  Front Neural Circuits       Date:  2022-07-04       Impact factor: 3.342

5.  Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig.

Authors:  O Piot; J Betschart; I Grall; S Ravard; C Garret; J C Blanchard
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

6.  Blockade of neurokinin-3 receptors modulates dopamine-mediated behavioral hyperactivity.

Authors:  Chinwe A Nwaneshiudu; Ellen M Unterwald
Journal:  Neuropharmacology       Date:  2009-06-03       Impact factor: 5.250

7.  Infusion of the substance P analogue, DiMe-C7, into the ventral tegmental area induces reinstatement of cocaine-seeking behaviour in rats.

Authors:  Franca M Placenza; Paul J Fletcher; Susan Rotzinger; Franco J Vaccarino
Journal:  Psychopharmacology (Berl)       Date:  2004-05-27       Impact factor: 4.530

8.  Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits.

Authors:  Judith A Siuciak; Sheryl A McCarthy; A N Martin; D S Chapin; J Stock; D M Nadeau; S Kantesaria; D Bryce-Pritt; S McLean
Journal:  Psychopharmacology (Berl)       Date:  2007-06-10       Impact factor: 4.415

9.  The insertion/deletion polymorphism of the angiotensin converting enzyme (ACE) in Parkinson's disease.

Authors:  Spiridon Papapetropoulos; Kostantinos Glynos; Zongmin Zhou; Stylianos E Orfanos; Georgia Mitsi; Andreas Papapetropoulos
Journal:  Open Neurol J       Date:  2008-10-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.